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ABSTRACT
The development of radiolabeled small peptide or peptidomimetic ligands can bind platelets and their specifi c 
expressed receptor have been suggested as a new approach to detect the clot location and, more essentially, 
to determine the age and morphology of the evolving thrombus. This new approach is focused on the use of a 
series of radiolabeled platelet GPIIb/IIIa receptor antagonists. 
Tirofi ban N-(butylsulfonyl)- 4-O-(4-(4-piperidyl)-L-tyrosine is a non-peptide tyrosine derivate. The aim of the study 
was to introduce radioactive-labeled tirofi ban as a specifi c imaging agent for acute DVT. 
The labeling was performed with technetium-99 in the presence of a stannous reducing agent. The labeled 
preparation showed fast blood clearance in a normal rat model (without induced thrombosis). More than 80 % 
of the injected dose was eliminated from the circulation in the fi rst hour after injection. Biodistribution and visu-
alization of the labeled molecule was carried out using an experimental model of thrombosis in a male Wistar 
rat. Planar images were obtained 30 and 60 min after application of 2 × 106 imp/min 99m-technetium-tirofi ban 
in the rat’s tail vein. Sensitivity and specifi city were determined using the ratio of ‘left leg positive for DVT’ to 
‘right leg negative for DVT’. The obtained ratio was 1.54 after 30 min and 5.04 after 60 min. These values were 
considered positive in the detection of acute DVT. The high DVT uptake shows that radiolabeled tirofi ban in 
the introduced rat model can be a promising agent for imaging the deep venous thrombosis (Fig. 7, Ref. 25). 
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Introduction
Venous thromboembolism is a complex vascular disease with 
a multifactorial pathogenesis that results in signifi cant morbidity 
and mortality. Its fi rst manifestation is deep venous thrombosis 
(DVT), which is most common and usually arises in the deep 
veins of the calf and spreads upwards. Pulmonary embolism is 
the second manifestation, which is more serious and occurs as a 
complication of DVT proximal to the deep calf veins (1).
Despite the remarkably high incidence of deep venous throm-
bosis (DVT) and pulmonary embolism (PE) in high-risk popula-
tions, hospitalized patients, and general population, the accuracy 
of the diagnoses of DVT and PE continue to be unreliable (2, 3).
All available imaging procedures (duplex ultrasound, magnetic 
resonance and contrast venography as a standard test for validating 
new diagnostic procedures) do not refl ect the metabolic activity of 
the clot and therefore they may overestimate the presence of ac-
tive clots (4). Only nuclear medical examinations can provide an 
image that includes the information on thrombus formation (25). 
The development of radioactive agents for scintigraphic imaging 
of DVT and PE is centered on the use of 99mTc-labeled peptides 
or peptidomimetics specifi c for resting or activated platelets (4-
9). They are smaller in size, their production is easier than that of 
monoclonal antibodies, their clearance from circulation is expected 
to be more rapid than that of radiolabeled proteins, and they are 
less likely to induce any immunologic reaction. At the same time, 
in most cases, their receptor specifi city and binding constants are 
as high as those of the monoclonal antibodies.
The 99m-technetium is a radionuclide that is inexpensive, 
easy to obtain worldwide, and it decays with emission of γ-rays 
(140 keV, 90 %) that can be effi ciently detected by γ-cameras. Its 
half-life (6 h) is long enough to perform examinations before ex-
cessive radioactive decay occurs, yet not too long to persist in the 
body long after the examinations are performed. 
Our approach was focused on the use of a series of radiolabeled 
platelet GPIIb/IIIa receptor antagonists (6, 10). The GPIIb/IIIa re-
ceptors are expressed on the membrane surface of activated plate-
lets and play an integral role in platelet aggregation and thrombus 
formation (10). Initial actions in thrombus formation frequently 
involve the activation of platelets by thrombogenic conditions and 
their subsequent aggregation. Platelet aggregation is mediated by 
fi brinogen which binds via the Arg-Gly-Asp (RGD) sequence to 
the GPIIb/IIIa receptor expressed on activated platelets. Since the 
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GPIIb/IIIa receptors are expressed only on the membrane surface of 
activated platelets, with 50 000–90 000 GPIIb/IIIa binding sites per 
platelet (2), the GPIIb/IIIa receptor makes an excellent target for 
the development of an imaging agent bound with high specifi city 
to activated rather than to inactive platelets. They would be differ-
entially incorporated in the thrombus (activated platelets) and the 
circulating platelets (resting or relatively less activated) (11, 12).
These molecules represent glycoprotein (GPIIb/IIIa) recep-
tor antagonists and they act as true biochemical markers of active 
thrombosis (10, 11).
One peptide, 99mTc-P280 (5), is approved by the Food and 
Drug Administration under the trade name AcuTect (99mTc-P280; 
Diatide, Inc.) (8), which can image acute thrombi but not old 
clots or PE.
The goal of our work was to use a small non-peptide derivate 
or peptidomimetic ligands with high specifi city for the GPIIb/IIIa 
receptor and incorporate a convenient radionuclide for imaging 
purposes was initiated from the already existing data presented 
using labeled peptides and GPIIb/IIIa receptor antagonists in 
the diagnosis of acute DVT. One promising GPIIb/IIIa recep-
tor antagonist is tirofi ban (AggrastatTM, Merck, Inc.,), a non-
peptide tyrosine derivate that inhibits fi brinogen binding (14) 
Tirofi ban hydrochloride monohydrate is chemically described as 
N-(butylsulfonyl)-O-(4-(4-piperidinyl)butyl)-L-tyrosine mono-
hydrochloride monohydrate (Fig. 1). The empirical formula of 
tirofi ban is C22H36N2O5S·HCl·H2O and its molecular weight of 
495.08 (2, 3). 
It is useful in combination with heparin and aspirin in the man-
agement of patients with unstable angina or non-Q-wave myocar-
dial infarction, including patients who may subsequently undergo 
percutaneous transluminal coronary angioplasty (PTCA0 (13, 14). 
Adjunctive therapy with a GP IIb/IIIa-receptor inhibitor can 
reduce the incidence of cardiac ischemic events, including subse-
quent myocardial infarction (MI) and death, in patients with non-
ST-segment-elevation acute coronary syndromes (5, 6).
When tirofi ban is prescribed and administered to the patient 
according to the recommended treatment, > 90 % inhibition is 
attained by the end of the 30-minute infusion. Platelet aggrega-
tion inhibition is reversible following cessation of the infusion of 
tirofi ban. Tirofi ban with a half-life of approximately 2 hours (15) 
is not strongly bound to plasma protein, and protein binding is 
concentration-independent in the range of 0.01–25 μg mL-1. The 
unbound fraction in human plasma is 35 %. The distribution vol-
ume of tirofi ban in the steady state is about 30 liters. 
To obtain the concentration of tirofi ban appropriate for labeling 
as a potential imaging radiopharmaceutical and at the same time in 
order not to receive its therapeutic effect, we have labeled tirofi ban 
with 99m-technetium and evaluated it in vitro and in rats with ex-
perimental venous thrombosis established and modifi ed afterwards 
according to the needs of a particular line of research (16, 17).
Material and methods
Materials
Tirofi ban
The structure of tirofi ban (tirofi ban hydrochloride monohydra-
te) N- (butylsulfonyl)-O-(4-(4-piperidinyl)butyl)-L-tyrosine mono-
hydrochloride monohydrate is shown in Figure 1. Tirofi ban hyd-
rochloride monohydrate is a white to off-white, non-hygroscopic, 
free-fl owing powder, with a molecular weight of 495.08. It is very 
slightly soluble in water (2, 3).
Isotope- 99m-technetium
The 99m-technetium-pertechnetate was obtained from a com-
mercial 99Mo/ 99mTc generator (10 GBq) (Schering /CIS-bioin-
ternational).
Radiolabeling
Labeling of tirofi ban with 99m-technetium
Tirofi ban was labeled using the method of direct labeling un-
der nitrogen. The kit freeze dried formulation contains a mixture 
of tirofi ban (20 nmol) dissolved in buffer (ethanol 96 %/PBS 0.01 
M, pH 7.3, 1:3 vol./vol.) and stannous chloride (10 nmol) as a 
reducing agent. Sodium (99mTc) perthechnetate (specifi c activ-
ity 740–4500 MBq/mL) containing 100 MBq/mL was added and 
the reaction mixture incubated for 15 min at room temperature.
The quality control was done by paper chromatography and 
instant thin layer chromatography (ITLC) using two solvents, 
namely 95 % acetone and saline. The percentage of labeled yield 
was recorded by gamma scanner (Veenstra Instrumenten B.V. 
VCS-103 V1.06).
Blood clearance
The 99m-technetium-tirofi ban was injected intravenously into Fig. 1. Chemical structure of Tirofi ban hydrochloride.
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rats. Blood samples were drawn from the previously prepared ca-
rotid vein using a sterile syringe at 5, 15, 30, 45 min and 1, 2, 4, 
6 and 24 h after injection. All samples were of the same volume 
and their radioactivity was measured in a gamma counter and 
compared with the standard.
In vitro platelet binding
The binding study was performed with rat and human plate-
lets isolated and treated according to protocol for platelet label-
ing (TROMBO-SCINT). Platelets were incubated for 30 min with 
tirofi ban radiolabeled with 99m-technetium. The percentage of 
binding was measured after one and two washing steps.
Animal studies
Male Wistar rats weighing 220–250 g were used throughout the 
study, anaesthetized by intraperitoneal injection of water solution 
of Nesdonal (concentration 20 mg/kg body weight).
Experimental animal model (18, 19)
Venous thrombosis was induced by ligature of the femoral 
vein in rats whose blood was made hypercoagulable by intrave-
nous administration of tissue thrombin (17). For the thrombosis 
model, the body temperature of rats was maintained at 37 °C. In 
brief, a short incision was made in the skin and subcutaneous tissue 
in the left groin region and the femoral neurovascular sheath was 
gently exposed (20). An approximately 10-mm long portion of the 
left femoral vein, distal to the inguinal ligament was isolated by 
rubbing it against the blade of a pair of forceps, and this segment 
collapsed. The collapsed segment of femoral vein between the 
clamps was traumatized by striking, and twenty units of thrombin 
(in 0.2 mL saline) were injected into the segment with a needle. A 
semiconstricting ligature was placed downstream to prevent the 
clot from slipping away.
Imaging
The thrombi developed in the rats were visualized using ti-
rofi ban radiolabeled with 99m-technetium. Planar images were 
obtained 30 and 60 min after the application of 2 × 106 counts/
min in 50–100 μL 99m-technetium-tirofi ban in the rat’s tail vein. 
Syringes should be measured before and after injection in order 
to determine accurately the radioactivity of material injected. The 
sensitivity and specifi city of the radiopharmaceuticals were deter-
mined using the ratio of ‘left leg positive for DVT’ to ‘right leg 
negative for DVT’ using the ROI technique.
Biodistribution
The biodistribution studies were carried out using the same 
experimental model of thrombosis in male Wistar rat and inject-
ing the radiolabeled products. After the desired time period had 
elapsed, the animals were sacrifi ced and the samples of organs of 
interest (heart, lung, liver, spleen, kidney, thrombotic and normal 
tissue) were collected and placed in pre-weighed counting tubes. 
These were then counted in a gamma counter together with the 
standard prepared from a known dilution of injected material (pref-
erably prepared at the time of injection). The total activity injected 
into each rat was determined and the activity remaining in the tail 
substracted. The uptake of labeled products in each tissue was cal-
culated and the specifi c uptake of the products quantifi ed using the 
ratio of ‘left leg positive for DVT’ to ‘right leg negative for DVT’.
Results
This study used a rat model of DVT to evaluate radiolabeled ti-
rofi ban platelets GPIIb/IIIa antagonist for its potential use in the de-
tection of rapidly growing venous thrombi. Two different methods 
of labeling were selected using 99m-technetium as radioisotope.
Labelling of tirofi ban with 99m-technetium
The specifi c activity of the radiolabelled product was 9.2 × 
1018 to 1.0 × 1019 counts/min/mol.
The percentage of obtained complex after labeling was more 
than 95 % (in acetone), more than 85% (in saline), with free 
pertechnetate (99mTcO4 -) less than 5 % (Fig. 2).
The labeled product was stable without changing the percent-
age of labeling after 2 h at room temperature.
After determination of radiochemical purity, it was concluded 
that the product could be tested for in vitro binding using normal 
platelets from humans and rats.
Fig. 2. ITLC radiochromatograms of 99mTc-tirofi ban in (a) 95% ac-
etone (b) saline.
Fig. 3. In vitro binding of rat and human platelets isolated and treated 
with radiolabeled tirofi ban.
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In vitro platelet binding
The binding study made for in vitro stability of platelets 
showed that 99mTc-labeled tirofi ban has a high percentage of la-
beling normal platelets from both, humans and rats, namely 69.30 
% and 68.79 %, respectively (Fig. 3). The stability of binding did 
not change after two washing steps, 58.63 % and 57.58 %.
Blood clearance
The obtained results showed that more than 80% of the injected 
dose from the labeled preparation of tirofi ban was eliminated from 
the circulation in the fi rst hour after injection (Fig. 4). 
Imaging studies
Whole-body images of distribution of 99m-technetium-tiro-
fi ban in normal and experimentally induced thrombosis in rats 
30 and 60 min after administration are presented in Figure 5. At 
30 and 60 min after injection, experimentally induced thrombi 
are visualized and compared with normal rat distribution of the 
tracer. The biological data demonstrated 99m-technetium-tirofi ban 
accumulation in the thyroid and liver. This accumulation could 
be related to the normal distribution of circulated platelets in the 
liver and spleen.
Biodistribution studies
The biological distribution data for the labeled 99m-techne-
tium-tirofi ban at different times after IV administration are pre-
sented in Figure 6. These biodistribution studies demonstrated 
a different behavior. The results obtained from the radioactivity 
distribution of 99m-technetium-tirofi ban at 30 and 60 min after IV 
administration clearly present an accumulation in critical organs. 
This is in accordance with the presence of destroyed platelets car-
rying the radioactive tirofi ban. However, the radiolabeled product 
was rapidly cleared from the circulation as represented by the low 
percentage of radioactivity in the heart and lung. The obtained ra-
tio of ‘left leg positive for DVT’ to ‘right leg negative for DVT’ 
was 1.54 after 30 min and 5.04 after 60 min for tirofi ban labeled 
with technetium (Fig. 7). These values were considered positive 
in the detection of acute DVT.
Fig. 4. Blood clearance of radiolabeled tirofi ban - 99mTc-tirofi ban 
in normal rat.
Fig. 5. Gamma camera images after IV injection of 99mTc-tirofi ban 
in rats
Normal rat 30 min after injection of 99m 
Technetium – Tirofi ban
Normal rat 60 min after injection of 99m 
Technetium – Tirofi ban
Rat with induced DVT 30 min after in-
jection of 99m Technetium – Tirofi ban
Rat with induced DVT 60 min after in-
jection of 99m Technetium – Tirofi ban
Fig. 6. Biodistribution studies in rat with induced DVT and after in-
jection of 99m Technetioum-labeled tirofi ban
Fig. 7. Left thrombotic/right normal leg ratio using ROI technique 
from gamma camera images after injection of 99mTechnetium-tiro-
fi ban.
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Discussion
Blood coagulation has long been considered an important 
factor in the pathogenesis of venous thrombosis. The relative 
contribution of stasis, altered coagulability of the blood, ves-
sel wall damage and circulation of leucocytes or platelets to the 
pathogenesis of venous thrombosis remains in dispute. On the 
other hand, it is known that a hypercoagulable state contributes 
signifi cantly to the thrombotic process. Animal models based on 
these activation mechanisms have been designed as a means of 
studying potential imaging agents for the diagnosis of acute DVT. 
The venous stasis thrombosis model consists of inducing blood 
stasis in the femoral vein of rats after prior injection of a proco-
agulant. A radionuclide imaging agent that binds to platelets being 
incorporated into an active thrombus but one which, if not bound, 
clears rapidly from the blood would have great potential for acute 
DVT detection.
Platelets expressed from the cell surface of GPIIb/IIIa recep-
tors undergo a conformational change that makes them available 
for binding with fi brinogen. Cross-linkage of activated platelets by 
the bivalent fi brinogen molecule to form a hemostatic plug is the 
primary episode of thrombosis. An imaging agent, ideally labeled 
with 99mTc and capable of binding actively and specifi cally to 
the GPIIb/IIIa receptor on activated platelets would give images 
of active or acute venous thrombosis.
The aim of the study was to evaluate tirofi ban as a specifi c 
imaging agent to GPIIb/IIIa receptors in a case of experimentally 
induced acute DVT in a rat experimental model. Radionuclide 
imaging offers considerable potential for a successful diagnostic 
agent which would address a few important criteria for rapid, non-
invasive, cost-effective and accurate diagnosis. The published data 
(7, 13, 19) indicate that radiolabeled tirofi ban binds preferentially 
to GPIIb/IIIa receptors on activated platelets and can differentiate 
acute DVT from chronic venous thrombosis. Radiolabeled tirofi -
ban is a functional rather than anatomical imaging modality. The 
use of radiotracers allows an understanding of the bioavailabil-
ity process, biodistribution and kinetics of any molecule labelled 
with an isotope, a procedure which does not alter the molecule’s 
biological properties. In the current work, technetium (to evaluate 
tirofi ban as a specifi c imaging agent to GPIIb/IIIa receptor in the 
case of experimentally induced acute DVT in the rat experimental 
model) was chosen as a radiotracer for biodistribution and imag-
ing studies in the experimental thrombosis induced in rats for its 
favourable radiation and physical characteristics, ready availability, 
possibility of labelling and low cost.
Commercially available technetium–apcitide (AcuTect), previ-
ously known as 99mTc-P280, which binds to the GPIIb/IIIa recep-
tor, is the fi rst imaging agent used in the clinical studies to detect 
acute DVT (21, 22). In this study, although the 99mTc–apcitide 
images obtained at 2 h after tracer injection show the greatest 
overall accuracy in comparison with earlier images, a combined 
analysis of image sets from at least two time points (30 min and 
60 min) provides greater accuracy in the detection of acute DVT 
in the patients. These results correlate with data obtained from 
the animal model. The 99m-technetium-tirofi ban is accurate in 
the detection of acute DVT, especially 60 min after application. 
The results obtained from the animal design experimental stud-
ies showed that the ratios of ‘left leg positive for DVT’ to ‘right 
leg negative for DVT’ for the radiolabelled preparation of tirofi -
ban are well within the range of that expected from a successful 
imaging agent.
Conclusion
Animal models provide convenient screening tools for ra-
diolabeled products before a new radiopharmaceutical is further 
developed in clinical trials (23).
The tirofi ban labelled with 99m-technetium was found to have 
good thrombus uptake in vivo. Obtained data indicate that radio-
labeled tirofi ban binds preferentially to GPIIb/IIIa receptors on 
activated platelets and can differentiate acute DVT from chronic 
venous thrombosis.
These results can be helpful in further clinical investigation 
of patients with acute DVT.
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